Taken together, our data identify a link between the Ran-GTPase nuclear transport pathway and key cancer signaling pathways, which warrant further study as inhibitors targeting nuclear transporters enter clinical evaluation as cancer therapeutics45,46. The gene discussed is RAN; the disease is cancer.